Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ALPHAMAB ONCOLOGY
康寧傑瑞生物製藥
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9966)

VOLUNTARY ANNOUNCEMENT
IND APPLICATION FOR A PHASE II CLINICAL TRIAL OF JSKN033 WAS OFFICIALLY ACCEPTED BY THE CDE

This announcement is made by Alphamab Oncology (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders (the "**Shareholders**") and potential investors of the Group about the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that the Investigational New Drug (the IND) application for a phase II clinical trial of JSKN033 (a high-concentration subcutaneous co-formulation consisting of anti-human epidermal growth factor receptor 2 ("**HER2**") bispecific antibody-drug conjugate ("**ADC(s)**") and programmed death ligand 1 ("**PD-L1**") immune checkpoint inhibitor) in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment of advanced cervical cancer (study number: JSKN033-202), has been officially accepted by the Center for Drug Evaluation (藥品審評中心) (the "**CDE**") of the National Medical Products Administration of China (國家藥品監督管理局) (the "**NMPA**").

JSKN033-202 is an open-label, multicenter phase II clinical trial designed to evaluate the safety, efficiency and pharmacokinetics/pharmacodynamics of JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment in patients with advanced cervical cancer. All patients will receive treatment with JSKN033 plus either cisplatin or carboplatin, with or without bevacizumab. The choice of platinum-based agent and the use of bevacizumab will be determined by the investigator based on the individual circumstances of the patients.

ABOUT JSKN033

JSKN033 is a global first subcutaneous co-formulation with JSKN003, the HER2 bispecific ADC and Envafolimab, the PD-L1 monoclonal antibody, developed by the Group. JSKN003 is a biparatopic HER2-targeting ADC, of which a topoisomerase I inhibitor is linked to the N glycosylation site of the antibody KN026 (a recombinant humanized anti-HER2 bispecific antibody) via the glycosite-specific conjugation. Envafolimab is a Fc fusion protein consisting of humanized anti-PD-L1 single domain antibody and human Immunoglobulin G1 Fc fragment, which has been approved by the NMPA as the global-first subcutaneous injection PD-L1 inhibitor in November 2021.

ABOUT THE COMPANY

The Company is a leading biopharmaceutical company in the PRC with a fully integrated proprietary technology platform in ADCs, bispecific antibodies and multi-functional protein engineering. The Company's highly differentiated in-house pipeline consists of ADCs, monoclonal antibodies and bispecific antibodies in staggered development status in oncology, including, among others, one product approved for marketing by the NMPA and multiple products in phase III or pivotal clinical trial stages. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop and/or ultimately market JSKN033 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, December 29, 2025

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.